Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get in-depth healthcare industry analysis with the unparalleled resources at Informa Pharma Intelligence.
Follow the evolution of the Zolgensma story and examine its possible implications for the future of product approval procedures.
Your free Pink Sheet pack includes:
The 2019 Titan of Pharma infographic is a snapshot of the industry’s top leaders and the businesses they oversee, including:
Pharma R&D Annual Review 2019 is based on the stats and data from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects, this whitepaper contains the whole nine yards:
The ball is in your court: tap into the industry expertise and experience of Ian Lloyd, backed by the rock-solid data from Pharmaprojects download Pharma R&D Annual Review 2019 from Citeline, today.
Listen to our special Spotify playlist while you read. We hope you enjoy this tongue-in-cheek collection of songs, specially curated as the perfect accompaniment to the Pharma R&D Annual Review 2019.
Skipta
When circumstances make meeting in person an impossibility, Skipta Gather is there. Don’t miss out on reaching your target audience because travel is curtailed and meetings are cancelled. Use Skipta Gather to conduct virtual sessions with verified physicians and get the job done.
Datamonitor Healthcare, Biomedtracker
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Topic Coronavirus Clinical Trials
Awareness, Pharma Consulting
Important insights into neoantigen-based immunotherapies and which developers are leading in this growing area.
Scrip
Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.
Topic Coronavirus Vaccines
Scrip
A five-day course will cost $2,340 for governments in developed countries and $3,120 for commercial payers. The US will get 100% of remdesivir manufactured by Gilead in July.
Topic Coronavirus
Citeline, Datamonitor Healthcare
Join our free 24-hour interactive webinar series on 21 July that will cover the latest insights and learning on COVID-19 from across the global Pharma and Biomedtech industry.
Topic Coronavirus
HBW Insight
The COVID-19 pandemic has impacted the consumer health and beauty products industries in different ways, and HBW Insight covers it all. We deliver all the latest regulatory, legislative, legal and commercial developments across the over-the-counter medicine, dietary supplement and the cosmetics sectors to keep you informed and strategically on target.
Topic Coronavirus
Pink Sheet
Pink Sheet invites you to go inside the recent personnel changes at key regulatory agencies around the globe – including US FDA, EMA, and England’s NICE – and how these new appointments will likely influence future regulation of the biopharma industry.
Topic Regulation
Scrip
Amid fears of a second wave of coronavirus infections and the increasing dominance of state-owned enterprises, private vaccine makers in China are struggling to make the best of the outbreak, BravoVax CEO Ke Wu tells Scrip in an exclusive interview.
Scrip
Vaccines veteran calls Moderna ‘shabby’ for lack of transparency and shares sell-off, and flags CanSino’s own forthcoming Phase II results.
Medtech Insight
Legislators at a 23 June Senate health panel hearing exploring prevention of future pandemics similar to COVID-19 discussed legislation they have recently introduced to resolve the current viral crisis.
Topic Coronavirus Legislation
Medtech Insight
Germany’s authorities are back on guard against COVID-19 following renewed regional outbreaks. Diagnostics manufacturers will continue to play a strong part in bringing the pandemic substantially under control, a recent industry association virtual conference heard.
Generics Bulletin
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Topic Coronavirus Drug Review
HBW Insight
FDA and FTC continue adding to total each has made during novel coronavirus pandemic. FTC's latest include peroxide gel and licorice as treatments; FDA’s emphasizes in warnings that three businesses' tests were not approved for OTC sales or for home use.
Pink Sheet
Considerations for switching from in-person to remote collection of patient- and observer-reported outcomes addressed in latest update to Q&A guidance, which also discusses Part 11 compliance requirements in the context of the pandemic and electronic collection of informed consent through MyStudies app.
Topic Coronavirus Clinical Trials
HBW Insight
04 Jul 2020
Scrip
04 Jul 2020
Scrip
03 Jul 2020
Scrip
03 Jul 2020
HBW Insight
03 Jul 2020
Pink Sheet
03 Jul 2020
Scrip
03 Jul 2020
Medtech Insight
03 Jul 2020
Scrip
03 Jul 2020
Pink Sheet
03 Jul 2020
Scrip
03 Jul 2020
Scrip
03 Jul 2020
Medtech Insight
03 Jul 2020
Generics Bulletin
03 Jul 2020
Generics Bulletin
03 Jul 2020
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
